Patent: 7,935,341
Summary for Patent: 7,935,341
| Title: | Antibodies to complementary peptides of thrombin or portions thereof |
| Abstract: | Disclosed are antibodies and antigen-binding fragments that bind to a complementary peptide having an amino acid sequence that is encoded by the complement of a nucleotide sequence encoding thrombin or a portion thereof. Such antibodies and antigen-binding fragments can be agonists or antagonists of thrombin receptor-mediated events. Also disclosed are methods of using the agonist antibodies and antigen-binding fragments of the invention to activate the non-proteolytically activated thrombin receptor (NPAR) in a subject in need of such treatment. In addition, methods of using the antagonist antibodies and antigen-binding fragments of the invention to inhibit activation of the NPAR in a subject in need of such treatment are disclosed. |
| Inventor(s): | Darrell H. Carney, John S. Bergmann, Gerald M. Fuller |
| Assignee: | Capstone Holding Corp |
| Application Number: | US11/521,596 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,935,341
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | SOLIRIS | eculizumab | Injection | 125166 | March 16, 2007 | 7,935,341 | 2026-09-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,935,341
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1934262 | ⤷ Start Trial |
| United States of America | 2008241149 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2007035406 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
